CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data
CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
Camp4 Therapeutics Q3 EPS $(0.37) Misses $(0.18) Estimate, Sales $1.899M Beat $1.850M Estimate
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
CAMP4 to Participate in Upcoming Investor Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.